We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Malibu Boats, MEDIFAST, OptimizeRx, Synergy Resources and Pioneer Natural
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Malibu Boats, Inc. (MBUU - Free Report) , MEDIFAST INC (MED - Free Report) , OptimizeRx Corp. (OPRX - Free Report) , Synergy Resources Corporation and Pioneer Natural Resources Company .
Here are highlights from Tuesday’s Analyst Blog:
Brokers Just Love These 5 Stocks
Sometimes you come across stocks that are just perfect, companies that seem to be doing everything right, growing revenue and earnings at strong double-digit rates and projecting solid sales and earnings growth ahead. Brokers just love these stocks and end up raising their estimates on them. But even with all these positives, for some reason, prices remain reasonable. There seems to be no reason to remain at the sidelines then. So it makes perfect sense to dive right in-
Malibu Boats, Inc.
Malibu Boats, Inc. operates as a designer, manufacturer and marketer of sport boats primarily in the United States. The Company sells its boats under two brands: Malibu and Axis Wake Research. Its sport boats used for water sports including water skiing, wakeboarding and wake surfing as well as for general recreational boating use.
Average broker rating 1
Zacks Rank #1 (Strong Buy)
VGM score A
Sales growth in the last fiscal year ending June was 76.28%
Expected sales growth this year 35.85% and next year 12.50%
EPS growth in the last fiscal year was 66.67%
Expected EPS growth this year 40.00% and next year 13.74%
Fiscal 2019 EPS estimate up 4.30%, 2020 EPS up 2.73% in the last 60 days
Valuation: The forward 12 months' P/E of 9.08X trails the 16.69X for the S&P 500
MEDIFAST INC
Medifast is a leading manufacturer and distributor of clinically proven weight loss and healthy living products and programs. Distribution is through websites, telemarketing, franchised weight loss clinics, medical professionals and multi-level marketing.
Average broker rating 1
Zacks Rank #2 (Buy)
VGM score B
Sales growth in the last fiscal year was 66.14%
Expected sales growth this year 47.72% and next year 24.98%
EPS growth in the last fiscal year was 101.75%
Expected EPS growth this year 47.19% and next year 26.91%
Valuation: The forward 12 months' P/E of 18.25X trails the 16.69X for the S&P 500. But whereas the S&P 500 is trading at its median value, MED is trading well below its median value of 23.68X.
OptimizeRx Corp.
OptimizeRx Corporation provides marketing and advertising solutions that seek to increase patient awareness and education about its clients' brands and then helps patients adhere to their routines. It is believed that this approach, facilitated through a platform connecting patients, physicians and pharmaceutical manufacturers, ultimately lowers cost for patients.
Average broker rating 1
Zacks Rank #1
Growth score A
Sales growth in the last fiscal year was 74.87%
Expected sales growth this year 35.17% and next year 29.65%
EPS growth in the last fiscal year was 223.8%
Expected EPS growth this year 61.54% and next year 55.16%
Valuation: The forward 12 months' P/E of 49.73X is below its median value of 90.67X and is at a significantly higher level than the S&P 500.
Synergy Resources Corporation
SRC Energy Inc. is an oil and natural gas exploration and production company. It engages in the acquisition, development, exploitation, exploration and production of oil and natural gas properties, primarily located in the Wattenberg field in the D-J Basin of northeast Colorado.
Average broker rating 1.4
Zacks Rank #2
VGM score A
Sales growth in the last fiscal year was 78.1%
Expected sales growth this year 18.27% and next year 10.22%
EPS growth in the last fiscal year was 63.77%
Expected EPS growth this year -11.50% and next year 14.79%
Valuation: The forward 12 months' P/E of 4.07X is below its median value of 5.82X and trails the S&P 500
Pioneer Natural Resources Company
Pioneer Natural Resources Company is a large, Texas-based independent exploration and production company that is focused on helping to meet the world's energy needs. Pioneer Natural Resources deliver industry-leading production and reserve growth through onshore, unconventional, oil and gas resource development in the United States, while providing opportunities for growth and enrichment for business partners, employees and the communities in which operate. The company provides administrative, financial and management support to United States and foreign subsidiaries that explore for, develop and produce oil, natural gas liquid and natural gas reserves.
Average broker rating 1.19
Zacks Rank #2
VGM score B
Sales growth in the last fiscal year was 72.59%
Expected sales growth this year 6.86% and next year 13.16%
EPS growth in the last fiscal year was 192.13%
Expected EPS growth this year 48.81% and next year 18.69%
Valuation: The forward 12 months' P/E of 14.18X is below its median value of 17.17X and trails the S&P 500.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Malibu Boats, MEDIFAST, OptimizeRx, Synergy Resources and Pioneer Natural
For Immediate Release
Chicago, IL – June 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Malibu Boats, Inc. (MBUU - Free Report) , MEDIFAST INC (MED - Free Report) , OptimizeRx Corp. (OPRX - Free Report) , Synergy Resources Corporation and Pioneer Natural Resources Company .
Here are highlights from Tuesday’s Analyst Blog:
Brokers Just Love These 5 Stocks
Sometimes you come across stocks that are just perfect, companies that seem to be doing everything right, growing revenue and earnings at strong double-digit rates and projecting solid sales and earnings growth ahead. Brokers just love these stocks and end up raising their estimates on them. But even with all these positives, for some reason, prices remain reasonable. There seems to be no reason to remain at the sidelines then. So it makes perfect sense to dive right in-
Malibu Boats, Inc.
Malibu Boats, Inc. operates as a designer, manufacturer and marketer of sport boats primarily in the United States. The Company sells its boats under two brands: Malibu and Axis Wake Research. Its sport boats used for water sports including water skiing, wakeboarding and wake surfing as well as for general recreational boating use.
Average broker rating 1
Zacks Rank #1 (Strong Buy)
VGM score A
Sales growth in the last fiscal year ending June was 76.28%
Expected sales growth this year 35.85% and next year 12.50%
EPS growth in the last fiscal year was 66.67%
Expected EPS growth this year 40.00% and next year 13.74%
Fiscal 2019 EPS estimate up 4.30%, 2020 EPS up 2.73% in the last 60 days
Valuation: The forward 12 months' P/E of 9.08X trails the 16.69X for the S&P 500
MEDIFAST INC
Medifast is a leading manufacturer and distributor of clinically proven weight loss and healthy living products and programs. Distribution is through websites, telemarketing, franchised weight loss clinics, medical professionals and multi-level marketing.
Average broker rating 1
Zacks Rank #2 (Buy)
VGM score B
Sales growth in the last fiscal year was 66.14%
Expected sales growth this year 47.72% and next year 24.98%
EPS growth in the last fiscal year was 101.75%
Expected EPS growth this year 47.19% and next year 26.91%
Valuation: The forward 12 months' P/E of 18.25X trails the 16.69X for the S&P 500. But whereas the S&P 500 is trading at its median value, MED is trading well below its median value of 23.68X.
OptimizeRx Corp.
OptimizeRx Corporation provides marketing and advertising solutions that seek to increase patient awareness and education about its clients' brands and then helps patients adhere to their routines. It is believed that this approach, facilitated through a platform connecting patients, physicians and pharmaceutical manufacturers, ultimately lowers cost for patients.
Average broker rating 1
Zacks Rank #1
Growth score A
Sales growth in the last fiscal year was 74.87%
Expected sales growth this year 35.17% and next year 29.65%
EPS growth in the last fiscal year was 223.8%
Expected EPS growth this year 61.54% and next year 55.16%
Valuation: The forward 12 months' P/E of 49.73X is below its median value of 90.67X and is at a significantly higher level than the S&P 500.
Synergy Resources Corporation
SRC Energy Inc. is an oil and natural gas exploration and production company. It engages in the acquisition, development, exploitation, exploration and production of oil and natural gas properties, primarily located in the Wattenberg field in the D-J Basin of northeast Colorado.
Average broker rating 1.4
Zacks Rank #2
VGM score A
Sales growth in the last fiscal year was 78.1%
Expected sales growth this year 18.27% and next year 10.22%
EPS growth in the last fiscal year was 63.77%
Expected EPS growth this year -11.50% and next year 14.79%
Valuation: The forward 12 months' P/E of 4.07X is below its median value of 5.82X and trails the S&P 500
Pioneer Natural Resources Company
Pioneer Natural Resources Company is a large, Texas-based independent exploration and production company that is focused on helping to meet the world's energy needs. Pioneer Natural Resources deliver industry-leading production and reserve growth through onshore, unconventional, oil and gas resource development in the United States, while providing opportunities for growth and enrichment for business partners, employees and the communities in which operate. The company provides administrative, financial and management support to United States and foreign subsidiaries that explore for, develop and produce oil, natural gas liquid and natural gas reserves.
Average broker rating 1.19
Zacks Rank #2
VGM score B
Sales growth in the last fiscal year was 72.59%
Expected sales growth this year 6.86% and next year 13.16%
EPS growth in the last fiscal year was 192.13%
Expected EPS growth this year 48.81% and next year 18.69%
Valuation: The forward 12 months' P/E of 14.18X is below its median value of 17.17X and trails the S&P 500.
Also see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.